Altimmune (ALT) closed at $2.23 on Oct 19, 2026, up 1.4% on the day. The stock is down 31.4% over the past month, down 20.9% over three months, down 38.2% year to date and down 42.7% over the past year. It trades 65.4% below its 52-week high of $6.44 and 2.8% above its 52-week low of $2.17. The close sits below its 50-day moving average ($2.98) and below its 200-day moving average ($3.37).
NextPick tracks ALT in its GLP-1 / Obesity basket alongside LLY, NVO, HIMS, VKTX and GPCR. As of Oct 19, 2026, the basket's money-flow score is -62 (strong outflow), and the basket is down 6.0% over five sessions. Over the past month ALT ranks 5th of 6 basket members by price change.
No — the Oct 19, 2026 close of $2.23 is 33.8% below the 200-day average of $3.37.
ALT closed 65.4% below its 52-week high of $6.44.
NextPick groups ALT with LLY, NVO, HIMS, VKTX and GPCR in its GLP-1 / Obesity basket.
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
